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Abstract: The provasopressin protein (proAVP) is expressed by invasive breast cancer and non-invasive breast cancer, or ductal 
carcinoma in situ (DCIS). Here we demonstrate the ability of the monoclonal antibody MAG1 directed against the C-terminal end of 
proAVP to identify proAVP in all cases examined of human invasive cancer and DCIS (35 and 26, respectively). Tissues were chosen 
to represent a relevant variation in tumor type, grade, patient age, and menopausal status. By comparison, there was 65% positive 
staining for estrogen receptor, 61% for progesterone receptor, 67% for nuclear p53, and 39% for c-Erb-B2 with the invasive breast 
cancer sections. Reaction with the normal tissue types examined (67) was restricted to the vasopressinergic magnocellular neurons of 
the hypothalamus, where provasopressin is normally produced, and the posterior pituitary, where these neurons terminate. The breast 
epithelial tissue sections on the tissue microarray did not react with MAG1. Previously, we demonstrated that polyclonal antibodies to 
proAVP detected that protein in all breast cancer samples examined, but there was no reaction with breast tissue containing fibrocystic 
disease. The results presented here not only expand upon those earlier results, but they also demonstrate the specificity and effectiveness 
of what may be considered a more clinically-relevant agent. Thus, proAVP appears to be an attractive target for the detection of invasive 
breast cancer and DCIS, and these results suggest that MAG1 may be a beneficial tool for use in the development of such strategies.
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Introduction
The  arginine  vasopressin  (AVP)  gene  is  expressed 
in small-cell lung cancer (SCLC) and breast cancer 
cells, while there appears to be a low incidence of its 
expression in non-neuroendocrine tumors.1 In normal 
tissues, AVP  expression  is  largely  restricted  to  the 
hypothalamus, where the provasopressin (proAVP) 
protein  is  packaged  into  secretory  vesicles  and 
undergoes enzymatic modification to generate AVP, 
vasopressin-associated  neurophysin  (VP-NP),  and 
vasopressin-associated  glycopeptide  (VAG).2  AVP 
can have a proliferative effect on cancer cells and it 
appears that the production of AVP by these cells aids 
in tumor growth and survival.3–5 VP-NP is important 
for the proper intracellular transport and processing 
of proAVP.6–8 The VAG region contains a conserved 
glycosylation  consensus  sequence,9–11  which  has 
been  shown  to  be  important  for  proAVP  folding,12 
but not essential for proper processing.13 Previously, 
we described a monoclonal antibody (mAb) directed 
against the VAG region of human proAVP, designated 
MAG1,  that  reacted  with  proAVP  forms  in  breast 
cancer  and  SCLC  cultured  cell  lysates  by  Western 
blot analysis.5,14,15 It also displayed immunoreactivity 
with SCLC tissue, but not with normal lung tissues, 
by  immunohistochemical  analysis.14  Earlier  studies 
performed using polyclonal antibodies raised against 
AVP  and VAG  indicate  that  invasive  breast  cancer 
and non-invasive breast cancer, or ductal carcinoma 
in situ (DCIS), contain proAVP products, but these 
products are not found in breast tissue with fibrocystic 
disease.16,17 Therefore, we wished to determine the 
specificity and effectiveness of a single mAb (MAG1) 
for the detection of proAVP in breast cancer and DCIS 
tissues by immunohistochemical analysis, since it may 
be  considered  a  more  clinically-relevant  agent.  We 
examined in-house tissue sections from 35 invasive 
breast cancer and 26 DCIS cases with the MAG1 mAb, 
and compared this reactivity with that seen in normal 
tissue  specimens  on  commercially  available  tissue 
microarrays, representing 66 different tissue types.
Materials and Methods
Antibodies
The MAG1 mAb is a mouse antibody of subclass IgG1 
directed against the C-terminal 18 amino acid resi-
dues of the proAVP protein. This sequence is located 
at the end of the VAG region of the protein, but does 
not  contain  the  glycosylation  site.  Production  and 
purification of the MAG1 mAb has been described 
elsewhere.14 The isotype-matched control antibody, 
MOPC21,  was  obtained  from  MP  Biomedicals 
(Irvine, CA).
Tissues
Formalin-fixed  biopsy  specimens  from  61  patients 
(35 invasive breast cancer and 26 DCIS cases) were 
obtained from archival tissue blocks from the Depart-
ment of Pathology at the Dartmouth Hitchcock Medical 
Center (Lebanon, NH). Information about the tumor 
grade, patient age, and other details are presented in 
Tables 1 and 2. Tissues were chosen to represent a 
clinically relevant variation in disease types, grade, 
and menopausal status. The invasive breast cancer 
tissues that were selected had undergone diagnostic 
immunohistochemical evaluation for estrogen recep-
tor, progesterone receptor, nuclear p53, and ErbB2 
expression. Sections from a formalin-fixed segment 
of anterior human hypothalamus that was obtained at 
autopsy were used as positive controls. The normal 
tissue microarrays CHTN2002N1 and CHTN2002X 
were  obtained  from  the  Cooperative  Human  Tis-
sue Network (University of Virginia Health System, 
Charlottesville, VA). Detailed information of these 
microarrays can be obtained at: http://faculty.virginia.
edu/chtn-tma/index.html. There are a combined total 
of 66 human tissue types represented on the microar-
rays, with a spot size of 0.6 mm (CHTN2002N1) or 
2 mm (CHTN2002X) at 4 µM thickness.
immunohistochemistry
All  steps  were  performed  at  ambient  temperature 
unless otherwise stated. Tissue sections (4–6 µM) and 
microarrays  were  deparaffinized  by  heat  exposure 
(60 °C for 10 min), washed in xylene (2 × 5 min), 
and rehydrated by washing (2 × 5 min) in descending 
concentrations  of  ethanol  (100%,  95%,  70%). 
After  washing  with  PBS  (2  ×  5  min),  the  tissues 
were  subjected  to  antigen  retrieval  by  incuba-
tion with trypsin or 0.01 M sodium citrate (pH 8.5) 
for  30  min  at  80  °C.14,18 Trypsin  was  removed  by 
washing with 95% ethanol (1 × 1 min), followed by 
PBS (1 × 10 min). Both antigen retrieval procedures 
were equally effective, however the citrate treatment 
resulted  in  lower  background  staining.  After  PBS 
washes (2 × 5 min), endogenous peroxidase activity MAg-1 detection of provasopressin in breast cancer and DCis
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Table 1. invasive breast cancer tissue specimens examined.
Tumor Menopausal Ini/Recd eR/pRe p53f c-erb-B2g
Gradea Gradeb statusc
iDC h Pre neg/neg pos pos
iDC h Pre ini neg/neg
iDC h Pre ini neg/neg neg
iDC h Post neg/neg pos neg
iDC h Post ini pos/neg pos pos
iDC h Post ini pos/pos neg
iDC h Post ini neg/neg
iDC h Post ini neg/neg neg
iDC h MALe
iDC i Post ini pos/pos pos pos
iDC i Post ini neg/pos pos pos
iDC i Post ini pos/pos neg
iDC i Post ini pos/pos pos pos
iDC i Post ini pos/pos neg pos
iDC i MALe ini pos/pos
iDC i Post Rec pos/neg pos
iDC i Post Rec neg/pos
iDC i Post Rec neg/neg pos pos
iDC L Post ini neg/neg pos neg
iDC L Post ini pos/neg neg neg
iDC L Post ini pos/pos pos neg
iDC L Post ini pos/pos
iDC L Post Rec pos/pos neg neg
iDC L Post ini pos/pos pos neg
iDC Post ini pos/neg neg neg
iDC (apocrine) n/ah Post ini neg/equivocal pos
iDC (colloid) n/a Post ini pos/pos pos neg
iDC (colloid) n/a Pre ini pos/pos pos neg
iDC (cribiform) n/a Post ini pos/pos neg pos
iDC (medullary) n/a Post ini neg/neg neg pos
iLC n/a Post ini pos/pos neg neg
iLC n/a Post ini pos/pos pos neg
iLC n/a Post Rec pos/pos pos pos
iLC n/a Post ini pos/pos neg neg
iLC n/a Post ini pos/pos pos neg
aTumor Type: (IDC) infiltrating ductal carcinoma, special types are indicated in parenthesis, (ILC) infiltrating lobular carcinoma.
bgrade: (h) high grade, (i) intermediate grade, (L) low grade.
cMenopausal status: (Pre) premenopausal, (Post) postmenopausal, (MALe) male subjects.
dini/Rec: initial or Recurrent disease.
eeR/PR: estrogen and progesterone receptor (Positive indicates greater than 15% staining of cancer cells, equivocal indicates 1%–15% staining, and 
negative is no staining).
fp53: nuclear p53 staining.
gc-erb-B2: Positive indicates 2+ or 3+ staining negative indicates 0 or 1+ staining according to hercepTest guidelines.
hn/a: not applicable.
note: Blank spaces indicate where information was not available.Keegan et al
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was quenched by incubation in 3% hydrogen peroxide 
for 5 min. Components of the Vectastain Elite ABC 
Kit (Vector Laboratories, Burlingame CA) were used 
for  subsequent  steps,  following  the  manufacture’s 
instructions.  Briefly,  tissue  sections  were  blocked 
with 10% normal horse serum (10–20 min), rinsed 
and  incubated  in  PBS  containing  MAG1  or  IgG1 
isotype control mAb (MP Biomedicals (Irvine, CA). 
The majority of the invasive breast cancer and DCIS 
specimens  were  incubated  overnight  at  4  °C  with 
0.25 µg/ml of antibody in PBS containing 1.5% horse 
serum. The normal tissue microarrays were incubated 
at ambient temperature with 1 µg/ml of antibody in 
PBS containing 0.4 M NaCl and 1.5% horse serum. 
These methods yielded identical results as indicated 
from the staining of replicate invasive breast cancer, 
DCIS, and human hypothalamus tissue sections that 
were included in the processing as positive controls for 
the microarrays. Antibody specificity was assessed on 
the invasive breast cancer and DCIS tissue sections 
by incubating them with antigen-blocked (10 µg/ml 
peptide) MAG1. After incubation with primary anti-
bodies,  the  tissue  sections  were  washed  with  PBS 
(3 × 5 min), and then reacted sequentially with bioti-
nylated goat anti-mouse IgG and ABC reagent. PBS 
washes (3 × 5 min) were performed in between each 
step. Staining was achieved using ImmunoPure Metal 
Enhanced DAB Substrate Kit (Pierce, Rockford, IL), 
with typical incubation times from 3–5 min. Tissues 
were then counterstained with Mayer’s hematoxylin 
(Sigma,  St.  Louis  MO),  dehydrated  in  ascending 
concentrations  of  ethanol,  washed  in  xylene,  and 
cover-slipped  using  Permount  mounting  medium 
(Fisher  Scientific,  Pittsburg  PA).  The  staining  of 
the sections and microarrays was recorded using a 
Micropublisher camera (Qimaging, Burnaby, British 
Columbia, Canada) connected to a BX51 or a BX40 
microscope (Olympus, Melville, NY).
Results
MAG1  was  found  to  react  with  all  35  invasive 
breast  cancer  and  all  26  DCIS  cases  examined, 
regardless of patient age, sex, tumor type, grade, or 
the status of the other biomarkers that were tested for 
(Tables 1 and 2). Of the invasive breast cancer cases, 
there were 30 (86%) infiltrating ductal carcinomas 
(IDC) and 5 (14%) infiltrating lobular carcinomas 
(ILC) used in this study. Of the IDC cases, 9 were 
high grade (30%), 9 were intermediate grade (30%), 
6 were low grade (20%), and 5 were special-type 
(17%), as indicated in Table 1. Special-type IDC’s and 
ILC’s are not routinely assigned a tumor grade. The 
age of the patients ranged from 39 to 92 years with 
1 patient in her 30’s (3%), 4 in their 40’s (11%), 7 in 
their 50’s (20%), 10 in their 60’s (29%), 8 in their 70’s 
(23%), 2 in their 80’s (6%), and 2 in their 90’s (6%). 
Two of the patients were males (6%). Twenty-nine 
of the female patients were recorded as postmeno-
pausal (88%) and 4 were recorded as premenopausal 
(12%). All of the tissues were from lesions at the 
Table 2. DCis tissue specimens examined.
DcIs Menopausal
Gradea statusb
h Pre
h Pre
h Pre
h Post
h Post
h Post
h Post
h Post
h Post
h Post
i Pre
i Pre
i Pre
i Pre
i Pre
i Pre
i Pre
i Post
i Post
i Post
i Post
i Post
i Post
i Post
L Pre
  Post
aDCis grade: (h) high grade, (i) intermediate grade, (L) low grade.
bMenopausal status: (Pre) premenopausal, (Post) postmenopausal.
note: Blank spaces indicate where information was not available.MAg-1 detection of provasopressin in breast cancer and DCis
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primary site. Five of the invasive breast cancers, for 
which there was data, represented recurrent disease 
(16%). Eighteen tissues were from tumors that were 
both  estrogen  and  progesterone  receptor  (ER/PR) 
positive. Twenty-two  of  the  34  sections  that  were 
screened  for  ER  were  positive  (65%),  and  twenty 
were positive for PR (61%), 7 were ER/PR negative 
and 6 were of a mixed receptor profile (approximately 
20% each). Nuclear p53 staining was present in 16 
of the 24 cases tested (67%). Intense membranous 
c-Erb-B2 immunostaining was present in 11 of the 28 
(39%) tissue sections examined (scores 2+ and 3+), 
while staining that rated 0 or 1+ according to the 
HercepTest criteria are listed as negative. Grading 
information  was  available  for  twenty-five  of  the 
tenty-six DCIS cases. Ten were high grade (40%), 
14 were intermediate grade (56%), and 1 was low 
grade (4%). Fifteen of the tissue sections were from 
postmenopausal  women  (60%)  and  11  were  from 
premenopausal women (44%). The age of the DCIS 
patients ranged from 39 to 75 years with 2 patients in 
their 30’s (8%), 11 in their 40’s (42%), 4 in their 50’s 
(15%), 4 in their 60’s (15%), and 1 in her 70’s (4%).
MAG1  reactivity  with  invasive  breast  cancer 
and DCIS tissue was blocked by co-incubation with 
excess synthetic antigen (Fig. 1), and MOPC21 iso-
type control displayed no reactivity with these tissues 
(not shown). Breast tissue that appeared to be nor-
mal and tissue containing benign fibrocystic disease 
that was adjacent to the invasive breast cancer and 
DCIS cells was also found to react with MAG1. This 
staining however, was consistently variable and less 
intense in contrast to that observed in the invasive 
breast cancer and DCIS tissues.
MAG1 and MOPC21 displayed a complete lack 
of immunoreactivity with 4 samples of normal breast 
epithelium tissue on the normal tissue microarrays 
(Fig. 2). Of the 318 different specimens representing 
66 tissue types on the microarrays, only the 2 posterior 
pituitary specimens were found to react with MAG1. 
Figure 1. MAG1 immunoreactivity was observed with all cases of breast cancer examined (magnification × 10). For invasive breast cancer, the figures 
show positive staining of sections from A) infiltrating ductal carcinoma, B) infiltrating lobular carcinoma, with a normal lobe present c) mucinous carcinoma 
cases. Co-incubation of MAg1 with synthetic peptide antigen blocked the MAg1 immunodetection of proAVP in these specimens D–F). For DCis, the 
figures show positive staining of sections from G) cribiform low grade, H) intermediate grade, and I) comedo high grade cases. Co-incubation of MAg1 
with synthetic peptide antigen blocked MAg1 immunodetection of proAVP in these specimens (not shown).Keegan et al
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This was anticipated due to the presence of vasopress-
inergic neuron storage terminals. Thus, the posterior 
pituitary  sections  served  as  an  internal  positive 
control for the microarrays. Staining of magnocellu-
lar neurons in sections of hypothalamus, localized to 
supraoptic nucleus region, displayed strong immuno-
reactivity with MAG1, but not with MOPC21. This 
staining was not evident in tissues from other regions 
of the brain or with some of the other tissues reported 
to express the vasopressin gene (see below).
Discussion
It has been known for some time that certain cancers can 
express neuropeptides, including AVP. The majority 
of studies concerning AVP expression by cancer cells 
have focused on SCLC, while far fewer have exam-
ined its expression by other types of cancer cells. The 
MAG1 mAb reacts with SCLC cells, while reactivity 
with the corresponding normal tissue was negative.14,15 
MAG1 also reacts with cultured breast cancer cells,5 
and we have demonstrated that proAVP is expressed 
by breast cancer and DCIS tissue.16,17 Those studies, 
however, were performed using polyclonal antibodies 
(pAb) raised against AVP and VAG or a mAb against 
vasopressin-associated  neurophysin.  The  anti-VAG 
and anti-AVP pAbs were able to detect proAVP in all 
of the breast cancer tissues screened, but a monoclonal 
antibody to neurophysin reacted with only one of the 
tissues tested.16 Since mAbs might be considered a 
more clinically-relevant than pAbs because of their 
Figure 2. MAg1 immunoreactivity with normal tissue. The MoPC21 mAb was used as an isotype control. Breast epithelium stained with MAg1 A–D). 
human hypothalamus stained with e) MAg1 F) or MoPC21. Posterior pituitary stained with G) MAg1 or H) MoPC21. Anterior pituitary I), Corpus 
luteum J), bronchus epithelium K), and gastric mucosa L) stained with MAG1. Magnification × 10 A–D, I–L), and × 20 e–H).MAg-1 detection of provasopressin in breast cancer and DCis
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homogeneity, production, and lack of irrelevant anti-
bodies  in  the  preparation,  we  undertook  an  immu-
nohistochemical  analysis  of  tissue  sections  from 
35 invasive breast cancer cases, 26 DCIS cases, and 
67 various normal tissue types, including human hypo-
thalamus, with the MAG1 mAb. We found that MAG1 
mAb recognized proAVP in all of the invasive breast 
cancer and DCIS cases examined. The invasive breast 
cancer specimens were tested for the expression of 
other common biomarkers, and it was found that 65% 
were positive for ER, 61% for PR, 67% for nuclear p53, 
and 39% for c-Erb-B2. Thus, proAVP was detected by 
MAG1 in all invasive breast cancer specimens, includ-
ing ER-positive and ER-negative cases. These results 
demonstrate the ability of the MAG1 mAb to stain 
breast cancers regardless of the status of common bio-
markers, disease type, grade, or the age and sex of the 
patient. These results are supported by earlier findings 
using polyclonal antibodies against proAVP that show 
that AVP was expressed in all invasive breast cancer 
and DCIS cases examined.16,17 Surprisingly, we found 
that MAG1 reacted with some of the non-cancerous 
tissue  adjacent  to  the  breast  cancer  or  DCIS  cells. 
Recent work indicates that genetic changes that alter 
that expression of proteins, such as Fas ligand (FasL), 
occur prior to morphological changes in peritumoral 
breast tissue.19 Thus, it is possible that the expression 
of neuropeptides, such as AVP expression, is associ-
ated with malignant transformation.
In  hypothalamus  tissue  sections,  proAVP 
expression  was  strictly  limited  to  regions  contain-
ing vasopressinergic neurons, where it is normally 
produced.  On  normal  tissue  microarrays,  MAG1 
immunoreactivity was observed only with specimens 
of posterior pituitary, where many of the vasopress-
inergic  neurons  terminate.  There  was  no  evidence 
of  proAVP  expression  with  the  remaining  human 
tissue  specimens,  representing  65  various  tissue 
types, contained on the microarray. The presence of 
AVP-related protein products in select cells of vari-
ous tissues such as the thymus, spleen, and of the 
gastrointestinal  system  has  been  demonstrated.20–22 
In other tissues where AVP-related immunoreactiv-
ity has been found, such as the testes, adrenal gland, 
and corpus luteum, there is question as to the whether 
the hormone is actually synthesized at that site.23–26 
Although samples of these tissues were represented 
on the microarrays, MAG1 displayed no discernable 
immunoreactivty with them. In the thymus tissue, the 
predominant form of neurophysin present is oxyto-
cin-related neurophysin, which suggests an inability 
to discriminate from vasopressin-related neurophysin 
in such cases. Under the staining conditions described 
here, MAG1 showed clear positive staining for the 
posterior pituitary samples on the microarrays and 
hypothalamus  sections.  Pulmonary  neuroendocrine 
cells in the bronchioles of normal lung tissue sections 
were also found to stain positive with MAG1 mAb,14 
however none were evident on the microarrays. These 
differences are most likely due to the absence of those 
few neuroendocrine-type cells from the small region 
of the tissue specimens present on the microarrays, 
but it is clear that proAVP expression is not abundant 
in the vast majority on normal tissues. In conjunction 
with our previous reports, proAVP has been detected 
in all of the 62 invasive breast cancer and 47 DCIS 
cases  examined  by  immunohistochemical  analy-
sis,16,17 thus it appears that the AVP gene is likely to 
be expressed by most, if not all invasive breast cancer 
and DCIS cells.
There appears to be a very low incidence of pro-
AVP expression in a wide variety of normal tissues, 
to  include  breast.  Recently,  we  demonstrated  that 
proAVP is produced by cultured breast cancer cells, 
proAVP products can be secreted from them, and AVP 
can promote their growth. Activation of the phospha-
tidylinositol 3-kinase pathway is critical for the neo-
plastic transformation of breast cells27 and thus the 
initiation of AVP gene activation may be a contribut-
ing factor to this event. While this remains to be seen, 
the fact that proAVP is present in all of the samples we 
have examined to date indicates that it is an attractive 
target for the development of detection and treatment 
strategies for breast cancer, and that MAG1 should 
prove to be useful in this respect.
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